RAPP: Leerink Initiates
Leerink Partners initiates coverage on Rapport Therapeutics with Outperform rating and $52 price target
Leerink Partners analyst Marc Goodman initiates coverage on Rapport Therapeutics (NASDAQ: RAPP ) with a Outperform rating and announces Price Target of $52.